The development of HDAC inhibitors as anticancer medications was expedited by the efficaciousness of romidepsin in phase I clinical trials for cutaneous and peripheral T-cell lymphoma. Here, HDAC9 is linked to peripheral T-cell lymphoma, not otherwise specified.